Effect of a Diagnostic Strategy Using an Elevated and Age-Adjusted D-Dimer Threshold on Thromboembolic Events in Emergency Department Patients With Suspected Pulmonary Embolism: A Randomized Clinical Trial.


Journal

JAMA
ISSN: 1538-3598
Titre abrégé: JAMA
Pays: United States
ID NLM: 7501160

Informations de publication

Date de publication:
07 12 2021
Historique:
entrez: 7 12 2021
pubmed: 8 12 2021
medline: 17 12 2021
Statut: ppublish

Résumé

Uncontrolled studies suggest that pulmonary embolism (PE) can be safely ruled out using the YEARS rule, a diagnostic strategy that uses varying D-dimer thresholds. To prospectively validate the safety of a strategy that combines the YEARS rule with the pulmonary embolism rule-out criteria (PERC) rule and an age-adjusted D-dimer threshold. A cluster-randomized, crossover, noninferiority trial in 18 emergency departments (EDs) in France and Spain. Patients (N = 1414) who had a low clinical risk of PE not excluded by the PERC rule or a subjective clinical intermediate risk of PE were included from October 2019 to June 2020, and followed up until October 2020. Each center was randomized for the sequence of intervention periods. In the intervention period (726 patients), PE was excluded without chest imaging in patients with no YEARS criteria and a D-dimer level less than 1000 ng/mL and in patients with 1 or more YEARS criteria and a D-dimer level less than the age-adjusted threshold (500 ng/mL if age <50 years or age in years × 10 in patients ≥50 years). In the control period (688 patients), PE was excluded without chest imaging if the D-dimer level was less than the age-adjusted threshold. The primary end point was venous thromboembolism (VTE) at 3 months. The noninferiority margin was set at 1.35%. There were 8 secondary end points, including chest imaging, ED length of stay, hospital admission, nonindicated anticoagulation treatment, all-cause death, and all-cause readmission at 3 months. Of the 1414 included patients (mean age, 55 years; 58% female), 1217 (86%) were analyzed in the per-protocol analysis. PE was diagnosed in the ED in 100 patients (7.1%). At 3 months, VTE was diagnosed in 1 patient in the intervention group (0.15% [95% CI, 0.0% to 0.86%]) vs 5 patients in the control group (0.80% [95% CI, 0.26% to 1.86%]) (adjusted difference, -0.64% [1-sided 97.5% CI, -∞ to 0.21%], within the noninferiority margin). Of the 6 analyzed secondary end points, only 2 showed a statistically significant difference in the intervention group compared with the control group: chest imaging (30.4% vs 40.0%; adjusted difference, -8.7% [95% CI, -13.8% to -3.5%]) and ED median length of stay (6 hours [IQR, 4 to 8 hours] vs 6 hours [IQR, 5 to 9 hours]; adjusted difference, -1.6 hours [95% CI, -2.3 to -0.9]). Among ED patients with suspected PE, the use of the YEARS rule combined with the age-adjusted D-dimer threshold in PERC-positive patients, compared with a conventional diagnostic strategy, did not result in an inferior rate of thromboembolic events. ClinicalTrials.gov Identifier: NCT04032769.

Identifiants

pubmed: 34874418
pii: 2786829
doi: 10.1001/jama.2021.20750
pmc: PMC8652602
doi:

Substances chimiques

Anticoagulants 0
Fibrin Fibrinogen Degradation Products 0
fibrin fragment D 0

Banques de données

ClinicalTrials.gov
['NCT04032769']

Types de publication

Equivalence Trial Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2141-2149

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn

Références

J Thromb Haemost. 2018 Apr;16(4):725-733
pubmed: 29431911
PLoS One. 2017 Jan 13;12(1):e0169268
pubmed: 28085911
Trials. 2020 Jun 3;21(1):458
pubmed: 32493383
Biometrics. 2004 Dec;60(4):919-25
pubmed: 15606412
JAMA. 2018 Feb 13;319(6):559-566
pubmed: 29450523
J Thromb Haemost. 2017 May;15(5):1040-1043
pubmed: 28296048
N Engl J Med. 2019 Nov 28;381(22):2125-2134
pubmed: 31774957
Lancet Haematol. 2017 Dec;4(12):e615-e621
pubmed: 29150390
JAMA Intern Med. 2018 Jun 1;178(6):812-819
pubmed: 29710111
Arch Intern Med. 2011 May 9;171(9):831-7
pubmed: 21555660
JAMA. 2006 Mar 8;295(10):1152-60
pubmed: 16522836
Lancet. 2017 Jul 15;390(10091):289-297
pubmed: 28549662
Eur J Emerg Med. 2019 Dec;26(6):458-461
pubmed: 31609876
Lancet. 2008 Apr 19;371(9621):1343-52
pubmed: 18424324
Clin Appl Thromb Hemost. 2012 Jan-Feb;18(1):20-6
pubmed: 21949040
Ann Emerg Med. 2013 Aug;62(2):117-124.e2
pubmed: 23433653
Eur J Emerg Med. 2021 Jun 1;28(3):165-166
pubmed: 33899776
JAMA. 2014 Mar 19;311(11):1117-24
pubmed: 24643601
J Thromb Haemost. 2020 Jun;18(6):1495-1500
pubmed: 32496023
Acad Emerg Med. 2018 Jul;25(7):828-835
pubmed: 29498138
Radiology. 2012 Feb;262(2):468-74
pubmed: 22187633
Thromb J. 2013 Jul 06;11(1):13
pubmed: 23829521
Crit Care Med. 2020 May;48(5):704-708
pubmed: 32079894
JAMA. 2020 Nov 17;324(19):1948-1956
pubmed: 33201202
Eur Respir J. 2019 Oct 9;54(3):
pubmed: 31473594
J Thromb Haemost. 2008 May;6(5):772-80
pubmed: 18318689
N Engl J Med. 2017 Oct 5;377(14):1357-1367
pubmed: 28976859
J Thromb Haemost. 2021 Jul;19(7):1832-1833
pubmed: 34176222

Auteurs

Yonathan Freund (Y)

Sorbonne Université, Improving Emergency Care FHU, Paris, France.
Emergency Department, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France.

Anthony Chauvin (A)

Emergency Department, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France.

Sonia Jimenez (S)

Emergency Department, Hospital Clínic, IDIBAPS, Barcelona, University of Barcelona, Catalonia, Spain.

Anne-Laure Philippon (AL)

Sorbonne Université, Improving Emergency Care FHU, Paris, France.
Emergency Department, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France.

Sonja Curac (S)

Emergency Department, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, Clichy, France.

Florent Fémy (F)

Emergency Department, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris University, Paris, France.
Toxicology and Chemical Risks Department, French Armed Forces Biomedical Institute, Bretigny-Sur-Orges, France.

Judith Gorlicki (J)

Emergency Department, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris, INSERM U942-MASCOT, Bobigny, France.

Tahar Chouihed (T)

Emergency Department, University Hospital of Nancy, Université de Lorraine, UMR_S 1116, Nancy, France.

Hélène Goulet (H)

Emergency Department, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, Paris, France.

Emmanuel Montassier (E)

Emergency Department, CHU Nantes, Nantes, France.

Margaux Dumont (M)

Emergency Department, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France.

Laura Lozano Polo (L)

Emergency Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Universitat Autònoma de Barcelona, Catalonia, Spain.

Pierrick Le Borgne (P)

Emergency Department, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.

Mehdi Khellaf (M)

Emergency Department, CHU Henri Mondor, INSERM U955, Assistance Publique-Hôpitaux de Paris, Paris, France.

Donia Bouzid (D)

Université de Paris, INSERM, IAME, F-75006 Paris, France.
Emergency Department, Bichat-Claude Bernard University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.

Pierre-Alexis Raynal (PA)

Emergency Department, Hôpital St-Antoine, Assistance Publique-Hôpitaux de Paris, Paris, France.

Nizar Abdessaied (N)

Emergency Department, Centre Hospitalier de St Denis, St Denis, France.

Saïd Laribi (S)

Tours University, Emergency Medicine Department, Tours University Hospital, Tours, France.

Jeremy Guenezan (J)

Emergency Department, University Hospital of Poitiers, Poitiers, France.

Olivier Ganansia (O)

Emergency Department, Groupe Hospitalier Paris-St Joseph, Paris, France.

Ben Bloom (B)

Emergency Department, Barts Health NHS Trust, London, United Kingdom.

Oscar Miró (O)

Emergency Department, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France.

Marine Cachanado (M)

Department of Clinical Pharmacology and Clinical Research Platform Paris-East (URCEST-CRC-CRB), Assistance Publique-Hôpitaux de Paris, Sorbonne University, St Antoine Hospital, Paris, France.

Tabassome Simon (T)

Sorbonne Université, Improving Emergency Care FHU, Paris, France.
Department of Clinical Pharmacology and Clinical Research Platform Paris-East (URCEST-CRC-CRB), Assistance Publique-Hôpitaux de Paris, Sorbonne University, St Antoine Hospital, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH